Chapter/Section Purchase

1 Relapsed Acute Myeloid Leukemia Drug Market Overview
1.1 Product Overview and Scope of Relapsed Acute Myeloid Leukemia Drug
1.2 Relapsed Acute Myeloid Leukemia Drug Segment by Type
1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 aNK Program
1.2.3 AT-9283
1.2.4 BI-836858
1.2.5 Binimetinib
1.2.6 BL-8040
1.2.7 Others
1.3 Relapsed Acute Myeloid Leukemia Drug Segment by Application
1.3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Comparison by Application: (2022-2028)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Relapsed Acute Myeloid Leukemia Drug Market Size Estimates and Forecasts
1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue 2017-2028
1.4.2 Global Relapsed Acute Myeloid Leukemia Drug Sales 2017-2028
1.4.3 Relapsed Acute Myeloid Leukemia Drug Market Size by Region: 2017 Versus 2021 Versus 2028
2 Relapsed Acute Myeloid Leukemia Drug Market Competition by Manufacturers
2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2017-2022)
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Relapsed Acute Myeloid Leukemia Drug Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Relapsed Acute Myeloid Leukemia Drug Manufacturing Sites, Area Served, Product Type
2.5 Relapsed Acute Myeloid Leukemia Drug Market Competitive Situation and Trends
2.5.1 Relapsed Acute Myeloid Leukemia Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Relapsed Acute Myeloid Leukemia Drug Players Market Share by Revenue
2.5.3 Global Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Relapsed Acute Myeloid Leukemia Drug Retrospective Market Scenario by Region
3.1 Global Relapsed Acute Myeloid Leukemia Drug Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Relapsed Acute Myeloid Leukemia Drug Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
3.3.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country
3.3.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
3.4.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country
3.4.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region
3.5.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
3.6.1 Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country
3.6.2 Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country
3.7.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Relapsed Acute Myeloid Leukemia Drug Historic Market Analysis by Type
4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2022)
4.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2022)
4.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2017-2022)
5 Global Relapsed Acute Myeloid Leukemia Drug Historic Market Analysis by Application
5.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2022)
5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2022)
5.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2017-2022)
6 Key Companies Profiled
6.1 4SC AG
6.1.1 4SC AG Corporation Information
6.1.2 4SC AG Description and Business Overview
6.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.1.5 4SC AG Recent Developments/Updates
6.2 AbbVie Inc.
6.2.1 AbbVie Inc. Corporation Information
6.2.2 AbbVie Inc. Description and Business Overview
6.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.2.5 AbbVie Inc. Recent Developments/Updates
6.3 Actinium Pharmaceuticals, Inc.
6.3.1 Actinium Pharmaceuticals, Inc. Corporation Information
6.3.2 Actinium Pharmaceuticals, Inc. Description and Business Overview
6.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.3.5 Actinium Pharmaceuticals, Inc. Recent Developments/Updates
6.4 Agios Pharmaceuticals, Inc.
6.4.1 Agios Pharmaceuticals, Inc. Corporation Information
6.4.2 Agios Pharmaceuticals, Inc. Description and Business Overview
6.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.4.5 Agios Pharmaceuticals, Inc. Recent Developments/Updates
6.5 Amgen Inc.
6.5.1 Amgen Inc. Corporation Information
6.5.2 Amgen Inc. Description and Business Overview
6.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.5.5 Amgen Inc. Recent Developments/Updates
6.6 Arog Pharmaceuticals, Inc.
6.6.1 Arog Pharmaceuticals, Inc. Corporation Information
6.6.2 Arog Pharmaceuticals, Inc. Description and Business Overview
6.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.6.5 Arog Pharmaceuticals, Inc. Recent Developments/Updates
6.7 Array BioPharma Inc.
6.6.1 Array BioPharma Inc. Corporation Information
6.6.2 Array BioPharma Inc. Description and Business Overview
6.6.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.7.5 Array BioPharma Inc. Recent Developments/Updates
6.8 Astellas Pharma Inc.
6.8.1 Astellas Pharma Inc. Corporation Information
6.8.2 Astellas Pharma Inc. Description and Business Overview
6.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.8.5 Astellas Pharma Inc. Recent Developments/Updates
6.9 Astex Pharmaceuticals, Inc.
6.9.1 Astex Pharmaceuticals, Inc. Corporation Information
6.9.2 Astex Pharmaceuticals, Inc. Description and Business Overview
6.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.9.5 Astex Pharmaceuticals, Inc. Recent Developments/Updates
6.10 AstraZeneca Plc
6.10.1 AstraZeneca Plc Corporation Information
6.10.2 AstraZeneca Plc Description and Business Overview
6.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.10.5 AstraZeneca Plc Recent Developments/Updates
6.11 AVEO Pharmaceuticals, Inc.
6.11.1 AVEO Pharmaceuticals, Inc. Corporation Information
6.11.2 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.11.5 AVEO Pharmaceuticals, Inc. Recent Developments/Updates
6.12 BioLineRx, Ltd.
6.12.1 BioLineRx, Ltd. Corporation Information
6.12.2 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.12.5 BioLineRx, Ltd. Recent Developments/Updates
6.13 Boehringer Ingelheim GmbH
6.13.1 Boehringer Ingelheim GmbH Corporation Information
6.13.2 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.13.5 Boehringer Ingelheim GmbH Recent Developments/Updates
6.14 Boston Biomedical, Inc.
6.14.1 Boston Biomedical, Inc. Corporation Information
6.14.2 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.14.5 Boston Biomedical, Inc. Recent Developments/Updates
6.15 Bristol-Myers Squibb Company
6.15.1 Bristol-Myers Squibb Company Corporation Information
6.15.2 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.15.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.16 Calithera Biosciences, Inc.
6.16.1 Calithera Biosciences, Inc. Corporation Information
6.16.2 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.16.5 Calithera Biosciences, Inc. Recent Developments/Updates
6.17 Celgene Corporation
6.17.1 Celgene Corporation Corporation Information
6.17.2 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.17.5 Celgene Corporation Recent Developments/Updates
6.18 Cornerstone Pharmaceuticals, Inc.
6.18.1 Cornerstone Pharmaceuticals, Inc. Corporation Information
6.18.2 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.18.5 Cornerstone Pharmaceuticals, Inc. Recent Developments/Updates
6.19 CTI BioPharma Corp.
6.19.1 CTI BioPharma Corp. Corporation Information
6.19.2 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.19.5 CTI BioPharma Corp. Recent Developments/Updates
7 Relapsed Acute Myeloid Leukemia Drug Manufacturing Cost Analysis
7.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
7.4 Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Relapsed Acute Myeloid Leukemia Drug Distributors List
8.3 Relapsed Acute Myeloid Leukemia Drug Customers
9 Relapsed Acute Myeloid Leukemia Drug Market Dynamics
9.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
9.2 Relapsed Acute Myeloid Leukemia Drug Market Drivers
9.3 Relapsed Acute Myeloid Leukemia Drug Market Challenges
9.4 Relapsed Acute Myeloid Leukemia Drug Market Restraints
10 Global Market Forecast
10.1 Relapsed Acute Myeloid Leukemia Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Relapsed Acute Myeloid Leukemia Drug by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Relapsed Acute Myeloid Leukemia Drug by Type (2023-2028)
10.2 Relapsed Acute Myeloid Leukemia Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Relapsed Acute Myeloid Leukemia Drug by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Relapsed Acute Myeloid Leukemia Drug by Application (2023-2028)
10.3 Relapsed Acute Myeloid Leukemia Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Relapsed Acute Myeloid Leukemia Drug by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Relapsed Acute Myeloid Leukemia Drug by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer